For this review we screened the literature for possible candidates of drug repurposing in ANOCA treatment and identified two promising targets: Soluble Guanylate Cyclase (sGC) Stimulators and Endothelin-1-receptor (ET-1) blockers, both originally approved for the treatment of pulmonary hypertension (PH). This evidence concerns the gene SGCB and pulmonary arterial hypertension.